Selected article for: "disease severity and RNA clearance"
Author: Xudan Chen; Yang Zhang; Baoyi Zhu; Jianwen Zeng; Wenxin Hong; Xi He; Jingfeng Chen; Haipeng Zheng; Shuang Qiu; Ying Deng; Juliana Chan; Jian Wang
Title: Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study
  • Document date: 2020_4_14
    • ID: 9j4ese89_29
    Snippet: Lopinavir/ritonavir is a fixed dose combination of anti-HIV protease inhibitors acting against the viral 3CL protease [21] . Although it has been used to treat COVID-19 [22], its benefits has not been confirmed in a clinical trial involving COVID-19 patients with pneumonia in Wuhan [16] . In our study, apart from lack of benefit, the use of lopinavir/ ritonavir tended to delay viral RNA clearance, even after adjusting for factors including diseas.....
    Document: Lopinavir/ritonavir is a fixed dose combination of anti-HIV protease inhibitors acting against the viral 3CL protease [21] . Although it has been used to treat COVID-19 [22], its benefits has not been confirmed in a clinical trial involving COVID-19 patients with pneumonia in Wuhan [16] . In our study, apart from lack of benefit, the use of lopinavir/ ritonavir tended to delay viral RNA clearance, even after adjusting for factors including disease severity.

    Search related documents:
    Co phrase search for related documents
    • benefit lack and disease severity: 1, 2, 3
    • clinical trial and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and dose combination: 1, 2, 3, 4, 5, 6, 7
    • clinical trial and pneumonia patient: 1, 2, 3, 4, 5
    • clinical trial and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • clinical trial and RNA clearance: 1, 2, 3, 4
    • clinical trial and viral RNA clearance: 1, 2
    • disease severity and dose combination: 1, 2
    • disease severity and pneumonia patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • disease severity and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • disease severity and RNA clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • disease severity and viral RNA clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • disease severity and viral RNA clearance delay: 1, 2
    • dose combination and protease inhibitor: 1, 2, 3, 4, 5
    • pneumonia patient and Wuhan pneumonia patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • RNA clearance and viral RNA clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • RNA clearance and viral RNA clearance delay: 1, 2, 3, 4